Table VIII.
Frequency of single nucleotide polymorphisms in patients with PA and in the control group according to PA activity.
| Gene marker | Control group, n (%) | P-value HWE | Inactive PA group, n (%) | P-value HWE | Active PA group, n (%) | P-value HWE |
|---|---|---|---|---|---|---|
| SIRT1 rs12778366 | ||||||
| Genotype | ||||||
| T/T | 647 (80.1) | <0.001 | 48 (76.2) | 0.007 | 68 (85.0) | 0.044 |
| T/C | 141 (17.5)a,b | 0 (0.0)a | 0 (0.0)b | |||
| C/C | 20 (2.5)c,d | 15 (23.8)d | 12 (15.0)c | |||
| Total | 808 (100.0) | 63 (100.0) | 80 (100.0) | |||
| Allele | ||||||
| T | 1,435 (88.8) | 96 (76.2) | 136 (85.0) | |||
| C | 181 (11.2) | 30 (23.8) | 24 (15.0) | |||
| FGFR2 rs2981582 | ||||||
| Genotype | ||||||
| G/G | 336 (41.6) | <0.001 | 25 (39.7) | <0.001 | 31 (38.8) | 0.005 |
| G/A | 429 (53.1) | 38 (60.3) | 46 (57.5) | |||
| A/A | 43 (5.3) | 0 (0.0) | 3 (3.8) | |||
| Total | 808 (100.0) | 63 (100.0) | 80 (100.0) | |||
| Allele | ||||||
| G | 1,101 (68.1) | 88 (69.8) | 108 (67.5) | |||
| A | 515 (31.9) | 38 (30.2) | 52 (32.5) | |||
| STAT3 rs744166 | ||||||
| Genotype | ||||||
| G/G | 154 (19.1)e | <0.001 | 6 (9.5) | 0.193 | 7 (8.8)e | 0.915 |
| G/A | 363 (44.9) | 34 (54.0) | 34 (42.5) | |||
| A/A | 291 (36.0)f | 23 (36.5) | 39 (48.8)f | |||
| Total | 808 (100.0) | 63 (100.0) | 80 (100.0) | |||
| Allele | ||||||
| G | 671 (41.5) | 46 (36.5) | 48 (30.0) | |||
| A | 945 (58.5) | 80 (63.5) | 112 (70.0) |
SIRT1 rs12778366 T/C genotype is significantly less frequent (P<0.001) in inactive PA compared with the control group
SIRT1 rs12778366 T/C genotype is significantly less frequent (P<0.001) in active PA compared with the control group.
SIRT1 rs12778366 C/C genotype is significantly less frequent (P<0.001) in active PA compared with the control group.
SIRT1 rs12778366 C/C genotype is significantly more frequent (P<0.001) in inactive PA compared with the control group.
FGFR2 rs2981582 G/G genotype is significantly less frequent (P=0.022) in active PA compared with the control group.
FGFR2 rs2981582 A/A genotype is significantly more frequent (P=0.029) in active PA compared with the control group. PA, pituitary adenoma; SIRT1, sirtuin 1, FGFR2, fibroblast growth factor receptor 2; STAT3, signal transducer and activator of transcription 3; HWE, Hardy-Weinberg equilibrium.